BioDelivery Sciences International announced Monday that it had received a final $2.5 million milestone payment for its oral pain patch.
The payment was from Meda AB, the Raleigh company's Swedish partner in developing and commercializing Breakyl, which is marketed in the United States as Onsolis.
BioDelivery received a $2.5 million payment from Meda in May after the drug achieved registration and pricing approval in its first European Union country.
BioDelivery will also receive royalty payments on sales of Breakyl in the E.U. The drug is being launched in selective European countries this year, including Germany.
Sales of BioDelivery's Onsolis oral pain patch for cancer patients, which was approved by federal regulators in 2009, have been underwhelming in the United States.
But the company anticipates that new regulations recently adopted for narcotic painkillers will level the playing field.